Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 11/2011

01-11-2011 | Research Articles

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)

Authors: Elena María Martínez-Navarro, Joseba Rebollo, Ramón González-Manzano, Manuel Sureda, Elena Evgenyeva, Belén Valenzuela, Francisco José Fernández, Jerónimo Forteza, Antonio Brugarolas

Published in: Clinical and Translational Oncology | Issue 11/2011

Login to get access
Metadata
Title
Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)
Authors
Elena María Martínez-Navarro
Joseba Rebollo
Ramón González-Manzano
Manuel Sureda
Elena Evgenyeva
Belén Valenzuela
Francisco José Fernández
Jerónimo Forteza
Antonio Brugarolas
Publication date
01-11-2011
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 11/2011
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-011-0739-1

Other articles of this Issue 11/2011

Clinical and Translational Oncology 11/2011 Go to the issue

Research Articles

Fine-needle aspiration cytopathology in the diagnosis of Wilms tumor

Editorial

Antiangiogenic therapy of breast cancer. How did we get here? The road not taken

Educational Series / Red Series

Non-FDG PET in oncology

Special Articles

Ameloblastoma, a rare benign odontogenic tumour: an interesting tumour review targeting the role of radiation therapy

Educational Series / Yellow Series

A new era in the treatment of melanoma: from biology to clinical practice

Research Articles

VEGF-A-independent and angiogenesis-dependent tumour growth in patients with metastatic breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits